SAB Biotherapeutics Announces New Appointments to its Board of Directors
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully human polyclonal antibodies without the need for human serum, today announced the appointment of Mani Mohindru, PhD, and Mervyn Turner, PhD to its Board of Directors.
“We are excited to welcome Drs. Mohindru and Turner to our Board of Directors. Each industry executive brings a wealth of corporate strategy, drug development and financial expertise,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics. “Both Drs. Mohindru and Turner are joining SAB at a pivotal time as we continue to advance a new class of immunotherapies that leverage the native human immune response and match the evolution of human disease. We look forward to their contributions as we develop our robust pipeline, spanning multiple therapeutic areas, using our novel technology platform.”
Dr. Mohindru is a senior biopharmaceutical executive with several years of industry leadership as well as Wall Street experience. Most recently, she was the CEO of CereXis, a clinical-stage biopharmaceutical company developing treatments for rare tumors. Previously, Dr. Mohindru was Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics (Nasdaq: CARA), a company focused on developing therapies for pruritus and pain. Earlier, she served as Chief Strategy Officer at Curis, Inc. (Nasdaq: CRIS), where she was instrumental in the development of overall strategy for its oncology focused pipeline. Dr. Mohindru also spent several years as an equity research analyst covering the biotechnology sector at ThinkEquity, LLC, Credit Suisse and UBS. She also co-founded Immtox LLC, a privately-held biotechnology company, and was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health). Currently, she also serves as a Member of the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Dr. Mohindru received her PhD in Neurosciences from Northwestern University.
Dr. Mervyn Turner has nearly 35 years of experience in pharmaceutical drug discovery, research and development, licensing and business development, emerging markets strategy development and implementation. He currently operates his own consulting firm, MJ Turner Consulting, where he counsels biotech, pharma, venture capital and investment banking firms. He spent 27 years at Merck & Co. Inc., holding positions of increasing responsibility in Merck Research Laboratories before joining the company’s Executive Committee as Chief Strategy Officer. Since his retirement from Merck & Co., he is currently an Advisor to Bay City Capital, a San Francisco-based venture firm, to Bridge Medicines, a commercial incubator for early stage innovation based in New York City, and to Adagene, a China-based therapeutic antibody company. Dr Turner is also a member of the Board of EnGeneIC (Sydney, Australia), and the Chairman of the Board of LUNAC. He also serves on the Scientific Advisory Boards of Blade Therapeutics and Spinogenix. Additionally, Dr. Turner is a Senior Advisor to the Healthcare group of Lazard, a leading financial services and investment banking firm. He holds his PhD in Chemistry from the University of Sheffield.
“I am excited to have the opportunity to join the Board of SAB, to help foster the adoption of the company’s unique capabilities in meeting the therapeutic needs of both the current, and future pandemics,” said Mervyn Turner, PhD. “I also look forward to helping to drive the SAB platform into novel therapeutic areas outside infectious disease, where polyclonal antibody technology offers unique capabilities in areas of significant unmet medical need.”
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. SAB-185, a fully-human polyclonal antibody therapeutic candidate for COVID-19, is being developed with initial funding supported by the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services and the Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) Joint Project Lead for Enabling Biotechnologies (JPL-EB). In addition to COVID-19, the company’s pipeline also includes programs in Type 1 diabetes, organ transplant and influenza. For more information visit: www.sabbiotherapeutics.com or follow @SABBantibody on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005549/en/
Contact information
Melissa Ullerich
Tel: 605-695-8350
mullerich@sabbiotherapeutics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 09:15:00 EET | Press release
Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106145232/en/ Thales’ hardened OS enables Samsung's award-winning security chip to deliver hardware-based, quantum-resistant protection from the moment devices power on. Ultimately, it ensures that encrypted data and device credentials remain secure against both classical and quantum attacks, preserving confidentiality, integrity and long-term trust, even in a post-quantu
Heath Hoglund Joins Sisvel as Chief IP Officer7.1.2026 08:00:00 EET | Press release
Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, its patent licensing programmes, and leading on the formation and design of numerous patent pools and standards initiatives. The appointment creates a new Licensing and Programme Management leadership structure at Sisvel. This will strengthen collaboration between the functions, increasing Sisvel’s considerable growth potential. Licensing and Programme Management heads, Nick Webb and David Muus, will continue to lead their respective areas, retaining all current responsibilities. Heath Hoglund’s trac
SymphonyAI and Matas Group are Redefining Health & Beauty in the Nordics With AI7.1.2026 07:07:00 EET | Press release
In the ever-evolving health and beauty landscape, Matas Group continues to set the standard for innovation and customer care. As the largest retailer in its sector across Denmark, Sweden, Finland, and Norway, Matas Group is committed to delivering unified, data-driven experiences to millions of customers — both online and in-store. That commitment now takes a leap forward as Matas selects SymphonyAI, a global leader in Vertical AI platforms, as its partner to modernize category management across the entire enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107270530/en/ Exterior of a Matas Group retail store in Scandinavia. The leading Nordic health and beauty retailer is expanding its category management capabilities through a new partnership with SymphonyAI. Following its acquisition of KICKS in 2023, Matas identified a need for technology that could simplify, scale, and unify processes across its diverse market
Lenovo Unveils Breakthrough Personal AI Super Agent, Novel Adaptive Concepts, and Next-Gen Device Innovations Spanning Mobile, Gaming, Consumer and Commercial Portfolios at CES 20267.1.2026 03:00:00 EET | Press release
At CES® 2026, Lenovo™ unveiled a sweeping lineup of innovations across its wide portfolio, introducing smarter new personal AI experiences, first-of-its-kind proofs-of-concept, and major updates across its gaming, mobile, consumer, and commercial devices. From ThinkPad™ to ThinkBook™, ThinkCentre™, Yoga™, IdeaPad™, Legion, and Motorola, Lenovo is showing how its Smarter AI for All vision is coming to life through more adaptive devices, bold new form factors, and AI software experiences designed to fit naturally into everyday life. The showcase is headlined by the debut of Lenovo and Motorola Qira, a new type of cross-device AI super agent that’s a Personal Ambient Intelligence System. “With Lenovo and Motorola Qira, we are entering a new era of personal AI: one designed around users, built on trust, and shaped by their control,” said Luca Rossi, President of Intelligent Devices Group, Lenovo. “At CES, personal AI comes to life across our portfolio, from breakthrough concepts and new sm
Lenovo Teams with NVIDIA on Gigawatt AI Factories Program to Accelerate Enterprise AI7.1.2026 03:00:00 EET | Press release
Today at Tech World @ CES 2026 at Sphere in Las Vegas, Lenovo (HKSE: 992) (ADR: LNVGY) unveiled the Lenovo AI Cloud Gigafactory with NVIDIA, expandingand reinforcing its partnership with NVIDIA through a shared commitment to accelerating hybrid AI adoption across personal, enterprise and public AI platforms. During his keynote,Lenovo Chairman and CEO Yuanqing Yang, joined by NVIDIA founder and CEO Jensen Huang, debuted this new gigawatt-scale AI factory program as a major advancement that enables AI cloud providers to bring next generation AI workloads and applications online faster, moving customers from creation to production at unprecedented scale. “In the AI era, value is no longer measured by compute alone, but also by how fast it delivers results,” said Yuanqing Yang, Chairman and CEO of Lenovo. “Together, Lenovo and NVIDIA are pushing the boundaries of AI factories to the gigawatt level, simplifying deployment of cloud-scale infrastructure that moves AI intelligence into product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom